Literature DB >> 26751187

Polio endgame: the global switch from tOPV to bOPV.

Julie Garon1, Katherine Seib1, Walter A Orenstein1, Alejandro Ramirez Gonzalez2, Diana Chang Blanc2, Michel Zaffran2, Manish Patel3.   

Abstract

Globally, polio cases have reached an all-time low, and type 2 poliovirus (one of three) is eradicated. Oral polio vaccine (OPV) has been the primary tool, however, in rare cases, OPV induces paralysis. In 2013, the World Health Assembly endorsed the phased withdrawal of OPV and introduction of inactivated poliovirus vaccine (IPV) into childhood routine immunization schedules. Type 2 OPV will be withdrawn through a globally synchronized "switch" from trivalent OPV (all three types) to bivalent OPV (types 1 and 3). The switch will happen in 155 OPV-using countries between April 17(th) and May 1(st), 2016. Planned activities to reduce type 2 outbreak risks post-switch include the following: tOPV campaigns to increase type 2 immunity prior to the switch, monovalent OPV2 stockpiling to respond to outbreaks should they occur, containment of both wild and vaccine type 2 viruses, enhanced acute flaccid paralysis (AFP) and environmental surveillance, outbreak response protocols, and ensured access to IPV and bivalent OPV.

Entities:  

Keywords:  eradication; immunization; inactivated polio vaccine; oral polio vaccine; polio; poliomyelitis; switch

Mesh:

Substances:

Year:  2016        PMID: 26751187     DOI: 10.1586/14760584.2016.1140041

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  25 in total

1.  Immunogenicity and safety evaluation of bivalent types 1 and 3 oral poliovirus vaccine by comparing different poliomyelitis vaccination schedules in China: A randomized controlled non-inferiority clinical trial.

Authors:  Jingjun Qiu; Yunkai Yang; Lirong Huang; Ling Wang; Zhiwei Jiang; Jian Gong; Wei Wang; Hongyan Wang; Shaohong Guo; Chanjuan Li; Shuyuan Wei; Zhaojun Mo; Jielai Xia
Journal:  Hum Vaccin Immunother       Date:  2017-03-01       Impact factor: 3.452

2.  Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis.

Authors:  Agustín Ciapponi; Ariel Bardach; Lucila Rey Ares; Demián Glujovsky; María Luisa Cafferata; Silvana Cesaroni; Aikant Bhatti
Journal:  Cochrane Database Syst Rev       Date:  2019-12-05

3.  Surveillance of adverse events following the introduction of inactivated poliovirus vaccine made from Sabin strains (sIPV) to the Chinese EPI and a comparison with adverse events following inactivated poliovirus vaccine made from wild strains (wIPV) in Jiangsu, China.

Authors:  Guodong Kang; Fenyang Tang; Zhiguo Wang; Ran Hu; Jing Yu; Jun Gao
Journal:  Hum Vaccin Immunother       Date:  2021-03-29       Impact factor: 3.452

Review 4.  Controlled Human Infection Models To Accelerate Vaccine Development.

Authors:  Robert K M Choy; A Louis Bourgeois; Christian F Ockenhouse; Richard I Walker; Rebecca L Sheets; Jorge Flores
Journal:  Clin Microbiol Rev       Date:  2022-07-06       Impact factor: 50.129

5.  Global epidemiology of vaccine-derived poliovirus 2016-2021: A descriptive analysis and retrospective case-control study.

Authors:  Yi An Lai; Xin Chen; Mohana Kunasekaran; Bayzidur Rahman; Chandini Raina MacIntyre
Journal:  EClinicalMedicine       Date:  2022-06-25

Review 6.  Poliomyelitis is a current challenge: long-term sequelae and circulating vaccine-derived poliovirus.

Authors:  Jorge Quarleri
Journal:  Geroscience       Date:  2022-10-19       Impact factor: 7.581

Review 7.  Global Polio Eradication - Way Ahead.

Authors:  Sunil Bahl; Pankaj Bhatnagar; Roland W Sutter; Sigrun Roesel; Michel Zaffran
Journal:  Indian J Pediatr       Date:  2018-01-05       Impact factor: 1.967

8.  Systematization of the Introduction of IPV and Switch from tOPV to bOPV in the Americas.

Authors:  Cristina Pedreira; Elizabeth Thrush; Barbara Jauregui
Journal:  J Infect Dis       Date:  2017-07-01       Impact factor: 5.226

9.  Disposing of Excess Vaccines After the Withdrawal of Oral Polio Vaccine.

Authors:  Sarah Wanyoike; Alejandro Ramirez Gonzalez; Samantha B Dolan; Julie Garon; Chantal Laroche Veira; Lee M Hampton; Diana Chang Blanc; Manish M Patel
Journal:  J Infect Dis       Date:  2017-07-01       Impact factor: 5.226

10.  The global switch from trivalent oral polio vaccine (tOPV) to bivalent oral polio vaccine (bOPV): facts, experiences and lessons learned from the south-south zone; Nigeria, April 2016.

Authors:  Bassey Enya Bassey; Fiona Braka; Rui Gama Vaz; William Komakech; Sylvester Toritseju Maleghemi; Richard Koko; Thompson Igbu; Faith Ireye; Sylvester Agwai; Godwin Ubong Akpan; Sisay Gashu Tegegne; Abdul-Aziz Garba Mohammed; Angela Okocha-Ejeko
Journal:  BMC Infect Dis       Date:  2018-01-27       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.